Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Chairman of Stem Cell Assurance and Traxxec Inc., (OTC:TRXX.PK), Updates Shareholders With Corporate Plans

Thu. June 04, 2009; Posted: 01:00 PM
Stocks RSS
BOCA RATON, FL, June 4, 2009 /PRNewswire-FirstCall via COMTEX/ -- TRXX | Quote | Chart | News | PowerRating -- As previously announced, Dr. Ferrans confirmed today that the Company plans to progress Stem Cell Assurance to attain reporting status. Dr. Ferrans also confirmed that together with the expansion of the company's centers into 5 new localities, the company will enter the healthcare treatment and cosmetic markets with established lines during quarter 3 2009. Stem Cell Assurance has also begun negotiations to engage in new product clinical trials in both Europe and the US. These plans will allow Stem Cell Assurance to develop new products and treatments and will also provide the ability to offer these and existing services across a greater market meeting identified and proven need.

Dr. Ferrans stated, "Today, adult stem cells are used to successfully treat advanced forms of cancer through the process of bone marrow transplantation. I am very excited about the very promising future of adult stem cell therapy. Numerous peer reviewed clinical trials have clearly demonstrated the potential for adult stem cell therapy to have enormous impact on the treatment of coronary artery disease, congestive heart failure, new onset diabetes, and a number of other neurologic, auto-immune, and musculoskeletal disorders. Stem Cell Assurance will help bring a broad array of consumer oriented services related to adult stem cells to help those seeking healthier lives."

Richard Ferrans, M.D. is the Chairman of Stem Cell Assurance and brings over 10 years experience as a physician leader in biotech, medical informatics, and care systems. Dr. Ferrans is the former Chief of Medical Informatics for LSU Health Sciences Center and Assistant Professor of Public Health and Clinical Assistant Professor of Medicine. He has been served as President and Founder of Avreo Inc., and Senior VP of Labnetics (now DxTech). He has also been a medical director of a large Medicare Advantage Plan, and the CMIO of a not-for-profit community hospital. Dr. Ferrans is a former staff member of the National Committee for Vital and Health Statistics, and has testified before the FDA and the U.S. Senate of policy and regulatory issues surrounding medical biotechnology and medical technology. Dr.

Ferrans is currently enrolled in the Harvard School of Public Health Masters in Healthcare Management Program.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

SOURCE Traxxec Ltd

 
For full details for TRXX click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.